Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 5/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.35 |
| ▸ | CFD | P00746 | 2/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3828590 | 0.76 | F10 (0.67) | F10 | |
| SCHEMBL3835389 | 0.76 | F10 (0.60) | F10 | |
| SCHEMBL3832110 | 0.76 | F10 (0.60) | F10 | |
| SCHEMBL14143313 | 0.75 | F10 (0.61) | F10KLKB1 | |
| SCHEMBL3828769 | 0.75 | F10 (0.51) | F10 | |
| SCHEMBL3830386 | 0.75 | F10 (0.49) | F10KLKB1 | |
| SCHEMBL3828800 | 0.75 | F10 (0.61) | F10 | |
| SCHEMBL3829947 | 0.74 | F10 (0.59) | F10 | |
| SCHEMBL3829081 | 0.74 | F10 (0.43) | F10KLKB1KMT2ASMN1; SMN2TP53 | |
| SCHEMBL3830235 | 0.74 | F10 (0.43) | F10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030141-B2 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2006-04-18 | — | — | US | claimed |
| EP-1465864-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | Warner-Lambert Company LLC (US) | 2004-10-13 | — | — | EP | claimed |
| WO-2003045912-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC (US) | 2003-06-05 | — | — | WO | claimed |
| US-20090221546-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | PFIZER INC | 2009-09-03 | — | — | US | disclosed |
| US-20080287674-A1 | Inhibitors of Factor XA and Other Serine Proteases Involved in the Coagulation Cascade | WARNER-LAMBERT COMPANY LLC | 2008-11-20 | — | — | US | disclosed |
| US-7407974-B2 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | PFIZER INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1671949-A2 | Substituted phenylamines and pyridinylamines | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-7030141-B2 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2006-04-18 | — | — | US | disclosed |
| EP-1465864-B1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER LAMBERT CO (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1465864-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | Warner-Lambert Company LLC (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003045912-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287674-A1 | Inhibitors of Factor XA and Other Serine Proteases Involved in the Coagulation Cascade | TFPI, F11, F2 | F10 11/4885KLKB1 116/4885CFD 38/4885 |
| US-20090221546-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | F11, F2, TFPI | F10 10/4885KLKB1 110/4885CFD 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.